Extrait

The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control. In addition an open-label metformin arm will be assessed

Critère d'inclusion

• Diabetes Mellitus, Type 2

Pays

• Argentina
• Croatia
• Estonia
• Germany
• Italy
• Korea, Republic of
• Lithuania
• Romania
• Russian Federation
• Slovakia
• Sweden
• Taiwan, Province of China
• Ukraine

Liens

• nct
• ictrp